Compounded semaglutide, explained

What compounded semaglutide is

Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone that reduces appetite and slows digestion. Novo Nordisk sells it as Wegovy (weight management, as a weekly pen and, since January 2026, a daily pill), Ozempic (type 2 diabetes) and Rybelsus (a diabetes tablet). Those products are made by Novo under FDA-inspected manufacturing and every dose is fixed.

A compounded version is prepared by a pharmacy, not the manufacturer. Under the FDA's definition, compounding is combining, mixing or altering ingredients "to create a medication tailored to the needs of an individual patient." The pharmacy buys the raw semaglutide, dissolves it to a chosen strength, and dispenses it against a prescription for a specific person. Two kinds of pharmacy do this: state-licensed 503A pharmacies, which compound for individual prescriptions and are not held to the FDA's manufacturing rules, and FDA-registered 503B outsourcing facilities, which are inspected by the FDA and follow good manufacturing practice but whose products are still unapproved.

During the 2022–2025 shortage of Wegovy and Ozempic, compounding was the legal route to a much cheaper product, and it became the core business of dozens of telehealth companies. That window is now mostly closed (see legal status below), which is why the products sold today are marketed as "personalized": custom doses, added ingredients, or non-injectable forms.

FDA: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." Source

The forms sold online: injection, tablets, drops, B12 blends

Weekly injection. The most common form: a multi-dose vial of semaglutide in sterile diluent, drawn up with an insulin syringe. Concentrations vary between pharmacies, and the patient measures each dose in "units", which is where most reported dosing errors originate.

Semaglutide with vitamin B12. Many providers add cyanocobalamin to the vial, marketed as reducing nausea. In its April 2026 policy update the FDA said that semaglutide plus B12, by the same route and within 10% of an approved strength, is still "essentially a copy" of the approved drug, so the add-on does not on its own make the product lawful to compound.

Oral tablets and sublingual drops. Compounded daily tablets, dissolving tablets and under-the-tongue drops are sold as a needle-free option, sometimes at lower prices than injections. They are a different route from the approved injection, which is one reason providers use them; how much semaglutide is absorbed from a compounded sublingual product has not been established the way it has for Wegovy's approved tablet.

What it must not be. The FDA has warned that some compounded products use semaglutide sodium or semaglutide acetate, salt forms that are "different active ingredients" from the approved drug with "no lawful basis" in compounding. A provider should be able to confirm its product is semaglutide base from a supplier on the FDA's Green List of acceptable GLP-1 ingredient sources.

Compounded semaglutide vs Wegovy and Ozempic

Same active ingredient, different everything else. The table sets out what actually differs.

Is compounded semaglutide still legal in 2026?

Mass compounding was lawful only while semaglutide was on the FDA's shortage list. The FDA declared the shortage resolved on 21 February 2025. Enforcement discretion for 503A pharmacies ended on 22 April 2025 and for 503B facilities on 22 May 2025. The compounding industry challenged the decision in court and lost; on 27 August 2026 the Fifth Circuit affirmed the FDA's ruling.

What remains lawful is a patient-specific prescription under section 503A: a compounder may make what would otherwise be a copy of Wegovy or Ozempic only if the prescriber determines that a change "made for an identified individual patient" will "produce a significant difference for that patient", and the FDA's enforcement policy tolerates a pharmacy filling four or fewer such prescriptions a month for a given product. Telehealth providers rely on this when they sell custom doses, B12 blends or oral forms. The FDA has not spelled out what documentation a prescriber must keep, and state pharmacy boards set additional rules; Ohio's board, for example, has said that adding B12 alone is not enough.

Enforcement and litigation have shaped the market more than the statute. The FDA sent warning letters to compounded-GLP-1 sellers, including Hims & Hers' Hers brand, on 9 September 2025, and to 30 telehealth companies on 20 February 2026 for implying their products were the same as approved drugs and for hiding which pharmacy made them. Novo Nordisk reported 132 lawsuits and 44 permanent injunctions against sellers by August 2025. In February 2026 Hims & Hers launched a $49 compounded semaglutide pill, drew an FDA statement and a referral to the Department of Justice, withdrew it within two days, and a month later settled with Novo to sell brand-name Wegovy instead. As of September 2026 Hims & Hers and Ro list no compounded semaglutide on their sites.

The practical test in 2026: a provider should name its pharmacy, explain why your prescription is patient-specific, and never describe the product as "the same as Wegovy" or "FDA-approved".

Is compounded semaglutide safe?

Semaglutide has the same risk profile in any form. The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents, contraindicates use in people with a personal or family history of medullary thyroid cancer, and lists nausea (44% of patients on 2.4 mg versus 16% on placebo), diarrhea, vomiting and constipation as the most common side effects. A compounded product adds risks that come from how it is made and measured.

By 31 May 2026 the FDA had received 990 adverse-event reports associated with compounded semaglutide. The agency notes that state-licensed pharmacies are not required to report to it, so the count is likely low. The most specific hazard the FDA has described is dosing error from multi-dose vials: patients who drew 50 units instead of 5, prescribers who wrote 25 units instead of 0.25 mg, and as a result doses of 5 to 20 times what was intended, with effects ranging from severe vomiting and dehydration to fainting, acute pancreatitis and gallstones, some requiring hospital care.

The other documented problems are unapproved salt forms, raw ingredient from unverified suppliers, and counterfeit products sold as "for research purposes only". None of these apply to an approved product; all of them depend on the pharmacy and the provider you choose.

Educational information, not medical advice. Whether semaglutide in any form is right for you is a decision for a licensed clinician. The FDA's current statement is here.

What compounded semaglutide costs

Telehealth providers advertise compounded semaglutide at headline prices of roughly $60 to $179 a month. Those figures are almost always the lowest starting dose, and usually come with either a separate membership fee ($39–$149 a month) or a prepaid multi-month term. Ongoing prices after the first month cluster at $149 to $299 a month where providers publish them. Always add the membership: a $75 medication price plus a $75 membership is $150.

Brand-name pricing has moved a long way toward those numbers. Novo sells the Wegovy pen for $349 a month directly (with a $199 price for the first two monthly fills for new patients until 31 December 2026), the Wegovy pill for $149, $199 or $299 a month depending on dose, and multi-month subscriptions through Ro, WeightWatchers and LifeMD from $249 a month. Novo has also announced a cut in the list price of Wegovy and Ozempic to $675 a month from 1 January 2027.

Every provider price on Rate GLP-1 carries a capture date and a source link. The cheapest GLP-1 without insurance table ranks the providers we track by all-in monthly cost across compounded and brand-name options, and each provider profile shows its full plan table under "What it costs".

How to choose a provider that sells it

Each provider profile on this site has an "Is it legit?" section that answers these four questions with sources:

• A clinician licensed in your state reviews your intake and makes the prescribing decision; no instant approvals.
• The compounding pharmacy is named and can be checked with the state board of pharmacy (503A) or the FDA's list of registered outsourcing facilities (503B).
• The product is described honestly: not "the same as Wegovy", not "FDA-approved", and the ingredient is semaglutide base, not a salt form.
• Price, dose changes and cancellation are in writing before you pay, including how a multi-month plan is cancelled and what happens to the price as your dose increases.